NP213 (Novexatin®) : A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile
© The Author(s) 2020. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology..
NP213 (Novexatin®) is a novel antifungal peptide specifically designed for the topical treatment of onychomycosis. NP213 was designed using host defense peptides (HDP), essential components of the innate immune response to infection, as a template. NP213 is a water-soluble cyclic fungicidal peptide that effectively penetrates human nail. NP213 demonstrated a promising preclinical and clinical safety profile, with no evidence of systemic exposure following topical application to the skin and nails. NP213 was efficacious in two phase IIa human trials with 43.3% of patients having no fungi detectable by culture of fragments from NP213-treated nails after 180 days in the first study and likewise 56.5% of patients were culture negative for dermatophytes after 360 days in the second phase IIa study. In both trials, NP213 was applied daily for only 28 days in marked contrast to other topical onychomycosis treatments that require application for up to 52 weeks. Patient reported outcomes from the phase IIa studies were positive with participants recording an improved appearance of their nails after only 14 days of application. All fungi identified in these studies were Trichophyton spp. NP213 (Novexatin®) is a promising, highly differentiated peptide-based candidate for the topical treatment of onychomycosis, addressing the infectious cause and cosmetic issues of this very common condition.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Medical mycology - 58(2020), 8 vom: 10. Nov., Seite 1064-1072 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mercer, Derry K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal |
|---|
| Anmerkungen: |
Date Completed 25.05.2021 Date Revised 23.08.2023 published: Print ErratumIn: Med Mycol. 2023 Aug 2;61(8):. - PMID 37611076 Citation Status MEDLINE |
|---|
| doi: |
10.1093/mmy/myaa015 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308180038 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308180038 | ||
| 003 | DE-627 | ||
| 005 | 20231225131203.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/mmy/myaa015 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1027.xml |
| 035 | |a (DE-627)NLM308180038 | ||
| 035 | |a (NLM)32232410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mercer, Derry K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NP213 (Novexatin®) |b A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.05.2021 | ||
| 500 | |a Date Revised 23.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ErratumIn: Med Mycol. 2023 Aug 2;61(8):. - PMID 37611076 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. | ||
| 520 | |a NP213 (Novexatin®) is a novel antifungal peptide specifically designed for the topical treatment of onychomycosis. NP213 was designed using host defense peptides (HDP), essential components of the innate immune response to infection, as a template. NP213 is a water-soluble cyclic fungicidal peptide that effectively penetrates human nail. NP213 demonstrated a promising preclinical and clinical safety profile, with no evidence of systemic exposure following topical application to the skin and nails. NP213 was efficacious in two phase IIa human trials with 43.3% of patients having no fungi detectable by culture of fragments from NP213-treated nails after 180 days in the first study and likewise 56.5% of patients were culture negative for dermatophytes after 360 days in the second phase IIa study. In both trials, NP213 was applied daily for only 28 days in marked contrast to other topical onychomycosis treatments that require application for up to 52 weeks. Patient reported outcomes from the phase IIa studies were positive with participants recording an improved appearance of their nails after only 14 days of application. All fungi identified in these studies were Trichophyton spp. NP213 (Novexatin®) is a promising, highly differentiated peptide-based candidate for the topical treatment of onychomycosis, addressing the infectious cause and cosmetic issues of this very common condition | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a antifungal | |
| 650 | 4 | |a antimicrobial peptide | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a dermatophyte | |
| 650 | 4 | |a onychomycosis | |
| 650 | 4 | |a tinea | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 650 | 7 | |a Antimicrobial Cationic Peptides |2 NLM | |
| 650 | 7 | |a Peptides, Cyclic |2 NLM | |
| 650 | 7 | |a cyclic fungicidal peptide NP213 |2 NLM | |
| 700 | 1 | |a Robertson, Jennifer C |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Lorna |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Colin S |e verfasserin |4 aut | |
| 700 | 1 | |a O'Neil, Deborah A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medical mycology |d 1997 |g 58(2020), 8 vom: 10. Nov., Seite 1064-1072 |w (DE-627)NLM097151785 |x 1460-2709 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2020 |g number:8 |g day:10 |g month:11 |g pages:1064-1072 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/mmy/myaa015 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2020 |e 8 |b 10 |c 11 |h 1064-1072 | ||